Shares of Idorsia Ltd (OTCMKTS:IDRSF – Get Free Report) rose 1% on Tuesday . The company traded as high as $3.95 and last traded at $3.95. Approximately 1,040 shares were traded during mid-day trading, a decline of 14% from the average daily volume of 1,209 shares. The stock had previously closed at $3.91.
Analyst Ratings Changes
Several brokerages have recently issued reports on IDRSF. HC Wainwright upgraded Idorsia from a “neutral” rating to a “buy” rating in a research note on Monday, September 15th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Idorsia in a research report on Friday, August 22nd. One investment analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy”.
View Our Latest Stock Analysis on IDRSF
Idorsia Trading Up 1.0%
About Idorsia
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases.
Further Reading
- Five stocks we like better than Idorsia
- Basic Materials Stocks Investing
- Keysight Technologies’ Surge: The Market Wakes Up to This AI Play
- The Risks of Owning Bonds
- Is American Express the Credit Stock For a K-Shaped Economy?
- Manufacturing Stocks Investing
- Powering Up: How a Credit Upgrade Fuels Vistra’s AI Ambitions
Receive News & Ratings for Idorsia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idorsia and related companies with MarketBeat.com's FREE daily email newsletter.
